Home Podcasts The Lancet Infectious Diseases in conversation with

The Lancet Infectious Diseases in conversation with

The Lancet Group 22 Episodes Jul 24, 2026

The editorial team of The Lancet Infectious Diseases interviews authors about their latest research and its impact on health, healthcare, and health policy. Topics include mpox diagnostics in Africa, long COVID, adaptive trials, and tuberculosis drug development.

Episodes

Fernando Tortosa and Ariel Izcovich on hantavirus infections Jul 24, 2026 1440 Fernando Tortosa and Ariel Izcovich discuss various aspects of hantavirus infections with a focus on the situation in Argentina, including transmission, epidemiology, clinical course, management, latest research developments, difficulties in conducting clinical trials, and future research priorities. The speakers also discuss the main findings and clinical implications of a study 'Use of tocilizum

Brecht Ingelbeen and Daniel Valia on a community-based antimicrobial stewardship intervention in Burkina Faso and DRC Jun 15, 2026 1615 Dr Brecht Ingelbeen and Dr Daniel Valia join Senior Editor Phoebe Hall to discuss a new trial in the journal (the CABU-EICO trial) testing a co-created behavioural intervention bundle to improve antibiotic use, patient management, and water, sanitation and hygiene in rural communities in Burkina Faso and DR Congo. They explain why the study focused on community prescribing (not hospitals), the pr

Sara Tartof and Matan Yechezkel on durability of doxycycline effectiveness against syphilis, gonorrhoea, and chlamydia after implementation of post-exposure prophylaxis in southern California May 7, 2026 1548 Sara Tartof and Matan Yechezkel discuss a new article in The Lancet Infectious Diseases about emerging doxycycline resistance against gonorrhoea and its wider implications for the implementation of doxycycline and the prevention of bacterial sexually transmitted infections. Click here to read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00123-4/fulltext The

Jenny Clarke and Herve Semukunzi Mar 9, 2026 1259 Dr Jenny Clarke and Herve Semukunzi discuss a study they and colleagues recently published with us titled ‘Infection- and vaccine-induced mpox antibodies: validation of a combined mpox IgG ELISA during the clade 1b outbreak in Rwanda’. They also discuss the reasons for the paucity of validated serological assays for mpox, particularly in outbreak regions where they are most urgently needed. Cli

Julia Moore Vogel and Danilo Buonsenso on long COVID Dec 19, 2025 1653 Dr Julia Moore Vogel and Dr Danilo Buonsenso discuss various aspects of long COVID including epidemiology, pathophysiology, underlying mechanisms, management, latest research developments, difficulties in conducting clinical trials, and future research priorities. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https:/

In Conversation with Steven Tong and Joshua Davis on adaptive platform trials Oct 23, 2025 1548 Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Conti

Anna Odone, Jesus Rodriguez-Manzano, and Alex Howard on artificial intelligence and infectious diseases Sep 16, 2025 1752 Professor Ana Odone, Dr Jesus Rodriguez-Manzano, and Dr Alex Howard discuss their new Series of papers on artificial intelligence and infectious diseases intended to support the infectious diseases community in understanding this evolving landscape and in actively shaping artificial intelligence integration into practice. Read the full Series here: https://www.thelancet.com/series-do/artificial-in

Catherine Liu and Joshua Hill on prevention and management of infections in people who are immunocompromised Aug 11, 2025 1107 Drs Catherine Liu and Joshua Hill of the Fred Hutchinson Cancer Center discuss their new Series of papers on the prevention and management of infections in people who are immunocompromised, with a focus on prevention of infections and diagnostic and antimicrobial stewardship. Read the Series papers: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00345-7/fulltext?dgcid=buzzsprou

Lilian Tina Minja and Norbert Heinrich on TB drug development Jul 9, 2025 1793 Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment. Read the trials: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00213-0/fulltext?dgcid=

Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile Jun 10, 2025 927 Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyon

Jan Felix Drexler and Fernando Bozza on Oropouche virus Apr 14, 2025 2117 Jan Felix Drexler and Fernando Bozza discuss their recent study published in the journal— “The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America” and its wider implications for Oropouche virus and other arboviruses transmission, expansion, surveillance, and control. Read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3

Prasad Kulkarni on dengue monoclonal antibodies Feb 23, 2024 1133 Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development. Read the full article: https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf

Oriol Mitjà on treatment of early syphilis in adults Jan 8, 2024 925 Oriol Mitjà discusses a new trial in The Lancet Infectious Diseases on the use of oral linezolid compared with benzathine penicillin G for the treatment of early syphilis in adults. He also highlights what the trial means for treatment of syphilis. Read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00683-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf

Sofia Viegas and Stefan Niemann on emerging bedaquiline resistance in Mozambique Nov 10, 2023 1475 Sofia Viegas and Stefan Niemann discuss a new article in The Lancet Infectious Diseases about emerging bedaquiline resistance in Mozambique and its implications for drug resistant tuberculosis and the fight to end tuberculosis. Read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00498-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf Continue this conver

Luciano Moreira and Henrik Salje on Wolbachia control of mosquito-borne infections Sep 27, 2022 1021 Luciano Moreira and Henrik Salje discuss a new article in The Lancet Infectious Diseases describing the use of the Wolbachia bacteria to control the spread of mosquito-borne dengue and chikungunya in Rio de Janeiro, Brazil. Read the full article: Estimating the effect of the wMel release programme on the incidence of dengue and chikungunya in Rio de Janeiro, Brazil Continue this conversation on s

Richard Maude on malaria chemoprophylaxis in Cambodia Sep 27, 2022 764 Richard Maude discusses a new article in The Lancet Infectious Diseases that assesses the efficacy of malaria chemoprophylaxis among forest goers in Cambodia. Read the full article: Antimalarial chemoprophylaxis for forest goers in southeast Asia Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/the

Ben Cowling on COVID-19 vaccines in Hong Kong Jul 15, 2022 1258 Ben Cowling discusses a new article in The Lancet Infectious Diseases describing the protection that vaccines are providing against COVID-19 in Hong Kong. Read the full article: Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/t

Hugh Adler on monkeypox in the UK May 26, 2022 1097 Hugh Adler discusses a new article in The Lancet Infectious Diseases describing the management and the clinical features for seven patients with monkeypox hospitalised in the UK between 2018 and 2021. Read the full article: Clinical features and management of human monkeypox: a retrospective observational study in the UK Continue this conversation on social! Follow us today at... https://thelance

Beate Kampmann, Karen Keddy, and Peter Ghazal on applying big data to childhood infectious diseases in LMICs Dec 14, 2021 1336 Prof Beate Kampmann, Dr Karen Keddy, and Prof Peter Ghazal discuss a new cross-journal Series in The Lancet Infectious Diseases and EBioMedicine addressing the potential for and challenge of applying big data to childhood infectious diseases in LMICs. Read the full Series: https://www.thelancet.com/series/big-data-childhood-infections-LMICs Continue this conversation on social! Follow us today a

Laura Cooper and Sam Okiror on polio eradication in Africa Oct 12, 2021 1294 A new article highlights how changing immunity profiles motivate the need for better responses to outbreaks of polio in Africa. Read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00453-9/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedica

Paul Chapman on a hookworm vaccine Aug 19, 2021 1257 Paul Chapman and colleagues presents the results of an innovative trial assessing the safety of vaccinating healthy volunteers with attenuated Necator americanus hookworm larvae. Read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00153-5/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.c

Josep Llibre on preventing SARS-CoV-2 transmission at concerts May 27, 2021 490 Josep Llibre discusses a trial on the impact of same-day testing for SARS-CoV-2 infection before a concert on new COVID-19 cases in Barcelona, Spain. Read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00268-1/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebo

Yap Boum on COVID-19 testing in low resource settings Mar 25, 2021 681 Yap Boum (MSF) discusses his study done in Cameroon, which developed a promising testing strategy for COVID-19 to optimise the available resources. Read the full article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00132-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook

The Lancet Infectious Diseases in conversation with

Episodes

Recommended